Patients who received radiation therapy within the last 4 weeks; radiation exposure may not exceed 30% of marrow area
For patients pre-registering after the completion of radiation therapy, documentation of a bone marrow aspirate and biopsy containing < 10% clonal plasma cells prior to start of radiation therapy
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment; patients who have received prior radiation to 50% or more of their total marrow volume will be excluded
Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy within 28 days prior to study entry
Prior radiation therapy is allowed to < 25% of the bone marrow, but is not permitted within 28 days prior to study registration
Concurrent malignancy requiring active therapy\r\n* Patients with localized prostate cancer having undergone surgery or radiation (field confined to =< 30% of marrow-bearing bone) at least 30 days prior to study treatment are eligible
Patients who have received radiation to more than 25% of marrow-bearing areas
No prior radiation to > 25% of the marrow.
Prior radiotherapy within 2 weeks of the first dose of study treatment; patients who have received radiation to more than 25% of the bone marrow are not eligible at any time
Patients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG; prior dexamethasone and/or surgery are allowed
Patients must not have received any prior chemotherapy, immunotherapy or bone marrow transplant for the treatment of their tumor; prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as 90 mg/m^2 /dose continuously during radiation therapy for 42 days) or dexamethasone is allowed
Participants who have received prior radiation therapy to > 25% of the bone marrow.
The patient has received radiation to ? 25% of his or her bone marrow within 4 weeks of the first dose of study drug.
Prior treatment with radiation therapy involving >=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.
Patients must not have had radiotherapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy
If the patient received previous radiation therapy, the total absorbed radiation dose at the bone marrow level must be ? 1 Gy
Radiation therapy to >30% of bone marrow prior to study entry;
Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow.
Prior radiation to chest or abdomen, or to > 30% of the marrow cavity
Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to 25% of the bone marrow within the past year are excluded; patients who received radiation for prostate cancer are also excluded
Subjects who have received radiation therapy targeting > 10% of the bone marrow space must have completed this at least 2 weeks prior to starting therapy with DS3032b
History of radiation therapy to >= 25% of the bone marrow for other diseases
Prior radiation to > 30% of the red marrow or to maximal tolerable level for any organ
Radiation therapy to more than 25% of the bone marrow
Prior radiation therapy is allowed to < 25% of the bone marrow; note: no radiation therapy within 30 days prior to registration for protocol therapy
A minimum of 12 weeks prior to start of vorinostat is required following prior large field radiation therapy (i.e., craniospinal, whole abdominal, total lung, > 50% marrow space)
Subjects who have received radiation therapy targeting > 10% of the bone marrow space must have completed this at least 2 weeks prior to starting therapy with AMG-232 + KRd
Prior radiation therapy irradiating more than 10% of total bone marrow
Participants may not have had radiation to > 25% of the bone marrow
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse events have not resolved to grade 1 or less (except alopecia) from agents administered more than 4 weeks earlier; patients must have completed prior biological therapies and/or targeted therapies >= 2 weeks prior to study enrollment; patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (i.e. radiation to > 25% of bone marrow)
Radiation: \r\n* Patients must not have received radiation (small port) for a minimum of two weeks prior to protocol therapy\r\n* Except for patients with a history of progressive disease, patients whose only site(s) of disease have been radiated are eligible if at least one lesion meets at least one of the criteria listed in sites of disease above\r\n* A minimum of 12 weeks prior to start of protocol therapy is required following large field radiation therapy (i.e. total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space)\r\n* A minimum of 6 weeks must have elapsed prior to start of protocol therapy for other substantial bone marrow radiation
Prior abdominal or pelvic radiation therapy or radiation therapy to > 10% of the bone\n             marrow at any time in the past or prior radiation therapy within the past 3 years to\n             the breast/sternum, dermal lesions, head or neck.
Prior radiation therapy to whole pelvis or greater amount of marrow-forming bone
6 weeks if other bone marrow radiation has been administered.
Patients may have received prior radiation therapy; radiation therapy must be completed at least 14 days prior to registration, and all toxicities related to prior radiation therapy must have resolved to CTCAE v4.0 grade 1 or lower; patients may not have had > 25% of their bone marrow radiated
No history of radiation therapy to >= 25% of the bone marrow for other diseases or history of anthracycline therapy
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment; patients who have received prior radiation to 50% or more of their total marrow volume will be excluded
Prior radiation therapy encompassing > 25% of bone marrow
Patients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), or radiation therapy to > 30% of the bone marrow, within 6 months of the first vaccination; treatment or salvage radiation therapy encompassing =< 30% of bone marrow must have been completed 4 weeks prior to the first vaccination
Prior radiation to maximally tolerated levels to any critical normal organ, or > 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)
Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization
Radiation therapy (other than palliative) =< 2 weeks prior to randomization; note: patients who have had > 25% of their functional bone marrow irradiated are not eligible for this trial
Patients who had radiation to greater than 25% marrow in the past 5 years
Has received prior radiation to > 50% of the bone marrow
Radiation including large bone marrow fields such as sternum or pelvis within 6 weeks prior to leukapheresis
Prior radiation to greater than 25% of the bone marrow or whole pelvis radiation
Prior radiation to greater than 25% of the bone marrow or whole pelvis radiation
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%; (ongoing small field radiation therapy for palliation only is allowed)
Prior radiation to maximally tolerated levels to any critical normal organ, or > 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)
No prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.
Prior radiation therapy is allowed provided exposure does not exceed an area of 25% of marrow space and occurred ? 6 weeks prior to the first dose of MEDI-551 (Arm A only)
Patients who have received radiation to more than 25% of marrow-bearing areas
Radiation therapy to greater than 25% of the bone marrow
No prior radiation therapy to the whole pelvis or to ?25% of the total bone marrow area.
prior radiation therapy with volume of bone marrow treated over 25%.
Prior radiation therapy allowed to < 25% of the bone marrow
Prior treatment with radiation therapy involving ? 25% of the hematopoietically active bone marrow within 42 days before the first dose of study drug.
Prior treatment with radiation therapy involving >= 25 percent (%) of hematopoietically active bone marrow.
Focal radiation therapy within 14 days prior to randomization; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow)
Prior treatment with radiation therapy involving ? 25% of the hematopoietically active bone marrow
Radiation therapy to 25% of bone marrow within 2 weeks of first dose
Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).
Received radiation therapy to more than 25% of the bone marrow-containing spaces < 84 days prior to first dose of study medication
Previous radiation therapy is allowed to less than 25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation.
Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within 30 days prior to registration for protocol therapy.
Prior radiation to ? 30% of bone marrow or any radiation therapy within 28 days prior to randomization
Diagnosis of another primary cancer for which the patient is currently undergoing radiation therapy, chemotherapy, or bone marrow transplant
Current systemic chemotherapy or radiation therapy that potentially causes bone marrow suppression that would preclude safe treatment of HSIL
Prior radiation therapy is allowed; patients must not have received any radiation within 3 weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding 40% of bone marrow volume
Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.
The patient has received radiation to ? 25% of his or her bone marrow within 4 weeks of the first dose of study drug.
